UCLA is the latest institution to join Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S. Through the I-O RPM program, BMS and the David Geffen School of Medicine at UCLA will conduct a range of early phase clinical studies. In addition, the company will fund positions within UCLA’s fellowship program in the UCLA Division of Hematology/Oncology.

“The I-O RPM research program is an important complement to Bristol-Myers Squibb’s broad research and development program for immuno-oncology,” said Laura Bessen, M.D., head of U.S. Medical, Bristol-Myers Squibb. “We look forward to working with UCLA in an effort to continue advancing the science in this innovative field of research and cancer treatment.”

The I-O RPM research program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high-risk, poor prognostic cancers, defined as a rare population malignancy. In September, Moffitt Cancer Center joined the program. Other partners include: Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.








This site uses Akismet to reduce spam. Learn how your comment data is processed.